{"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"43"}],"units":"Participants"}],"groups":[{"description":"Bendamustine 90 or 120 mg/m\\^2 administered as an IV infusion over 60 minutes on Days 1 and 2 of a 21-day Induction Cycle, with delays up to 2 weeks for neutrophil and platelet count recovery, for up to a 35-day cycle.","id":"BG000","title":"Phase 1: Bendamustine 90 or 120 mg/m^2"},{"description":"Bendamustine 120 mg/m\\^2 administered as an IV infusion over 60 minutes on Days 1 and 2 of each 21-day cycle (Cycles 2 through 12), with delays up to 2 weeks for neutrophil and platelet count recovery, for up to a 35-day cycle.","id":"BG001","title":"Phase 2: Bendamustine 120 mg/m^2"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"4.31","value":"8.7"},{"groupId":"BG001","spread":"4.93","value":"9.3"},{"groupId":"BG002","spread":"4.74","value":"9.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"14"}]}],"title":"1 to 6 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"13"}]}],"title":"7 to 11 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"16"}]}],"title":"12 to 20 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"13"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"30"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Includes 5 participants treated with bendamustine at 90 mg/m2 in Phase 1, and 6 participants treated with bendamustine at 120 mg/m2 in Phase 1, and 32 participants treated with the recommended phase II dose (RP2D) of bendamustine (120 mg/m2) in Phase 2."}